BIOLASE Inc. (NASDAQ:BIOL) does about 580.62K shares in volume on a normal day but saw 197550 shares change hands in Friday trading. The company now has a market cap of 16.89M USD. Its current market price is $0.49, marking a decrease of -1.42% compared to the previous close of $0.49. The 52 week high reached by this stock is $10.38 whilst the lowest price level in 52 weeks is $0.37. The script in recent trading has seen the stock touch a high of $0.50 and a low of $0.481.
BIOLASE Inc. (BIOL) has a 20-day trading average at $0.5446 and the current price is -95.31% off the 52-week high compared with 33.29% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5895 and its 200-day simple moving average is $2.7178. If we look at the stock’s price movements over the week, volatility stands at 4.53%, which increases to 8.23% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 37.18 to suggest the stock is neutral.
The consensus objective for the share price is $5.62, suggesting that the stock has a potential upside of 91.28% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 19, 2019 when The Benchmark Company initiated the stock to “Speculative Buy” and issued a price target of $2. WallachBeth downgraded its price target at $4-$2.50.
The current price level is -11.68%, -18.31%, and -82.25% away from its SMA20, SMA50, and SMA200 respectively, with the BIOL price moving above the 50-day SMA on February 17. BIOLASE Inc. (BIOL) stock is down -3.41% over the week and -8.21% over the past month. Its price is -25.15% year-to-date and -95.27% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$1.1 below consensus estimates by -$0.26. The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.64 and -$3.45 for whole year. BIOL’s earnings per share are forecast to shrink by -25.50% this year and 89.00% over next year. Expected sales for next quarter are $12.23 million, which analysts say will come at $48.47 million for the current fiscal year and next year at $58.29 million. In addition, estimates put the company’s current quarterly revenue at an average of $14.07 million.
To reach the target analysts have set, the stock logically needs to grow 91.28 percent from here.
Outstanding shares total 35.58M with insiders holding 11.45% of the shares and institutional holders owning 3.63% of the company’s common stock. The company has a return on investment of -34.70% and return on equity of -119.50%. The beta has a value of 1.40. Price to book ratio is 0.27 and price to sales ratio is 0.36.
